Ameriprise’s Audentes Therapeutics, Inc BOLD Stock Holding History

Ameriprise’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-46,726	Closed	-$2.8M	–	3802
2019 Q4	$2.8M	Buy	46,726 +39,106	+513%	+$1.47M	﹤0.01%	2565
2019 Q3	$214K	Sell	7,620 -2,135	-22%	-$72.9K	﹤0.01%	3535
2019 Q2	$370K	Sell	9,755 -9,785	-50%	-$376K	﹤0.01%	3430
2019 Q1	$762K	Sell	19,540 -10	-0.1%	-$287	﹤0.01%	3143
2018 Q4	$417K	Sell	19,550 -40,110	-67%	-$1.03M	﹤0.01%	3254
2018 Q3	$2.36M	Sell	59,660 -7,920	-12%	-$295K	﹤0.01%	2753
2018 Q2	$2.58M	Buy	67,580 +18,870	+39%	+$699K	﹤0.01%	2624
2018 Q1	$1.46M	Buy	+48,710	New	+$1.65M	﹤0.01%	2810

Ameriprise's BOLD Position: Q1 2020 in Review

Ameriprise sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 46,726 shares — an estimated $2.8M sold.

Ameriprise first reported a position in BOLD in Q1 2018 and held it in 8 quarters. The position peaked at $2.8M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Ameriprise reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Ameriprise sold 46,726 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $2.8M.
Ameriprise first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 8 quarters.
Ameriprise's Audentes Therapeutics, Inc position peaked at $2.8M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Ameriprise's 13F filing for Q1 2020, filed 15 May 2020.